BIVI stock forecast, quote, news & analysis

Key Takeaways

• BIVI shares have climbed roughly 15.7% over the trailing 30 days, rising from about $1.46 in early October to near $1.69.
• The gain follows a sharp mid-October slide toward $1.13 and a subsequent rebound tied to a wave of bezisterim clinical-data news.
• BioVie is a clinical-stage biotech with no product revenue, so its share price is driven primarily by clinical catalysts and financing developments.
• Recent momentum was supported by bezisterim data in Parkinson's disease and Long COVID, an NIH workshop invitation, and a late-breaking presentation selection.
• Over the trailing quarter the stock is roughly flat, masking a spike to an intraday high of $3.79 and a dip to an intraday low of $0.82.
• A going-concern disclosure and ongoing dilution risk remain key offsets to the company's clinical narrative.
• For additional detail, explore BIVI's Price Targets, Earnings, and Forecast on Tickeron's dedicated pages.
• Discover automated strategies by exploring Trending AI Robots.

BioVie (BIVI) Company Overview and Market Position

BioVie Inc. is a clinical-stage biopharmaceutical company developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease. Its lead program, bezisterim, is an orally administered small molecule being evaluated in Phase 3 for mild-to-moderate Alzheimer's disease, in Phase 2b for Parkinson's disease, and in a Long COVID program. The company's second asset, BIV201 (terlipressin), is in Phase 3 testing for life-threatening complications of liver cirrhosis and ascites and holds FDA Fast Track and Orphan Drug designations.

Headquartered in Carson City, Nevada, BioVie is a small, pre-revenue company with no approved products and limited commercialization infrastructure. Because it generates no meaningful revenue, investors follow the stock almost exclusively for binary clinical readouts, regulatory milestones, and financing events rather than traditional fundamentals. This profile makes BIVI highly sensitive to news flow and to shifts in risk appetite across the broader biotechnology sector.

BioVie (BIVI) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, BIVI has risen roughly 15.7%, moving from a closing price of about $1.46 on October 2 to near $1.69 in early November. The path was not linear: the stock fell to roughly $1.13 by mid-October before recovering sharply as a series of clinical announcements reached investors.

The trailing-quarter picture is more muted and far more volatile. Over approximately three months, the stock is essentially flat on a net basis, but that headline conceals extreme intra-quarter swings. In August, BIVI traded as low as $0.82 intraday before surging to an intraday high of $3.79, followed by a prolonged retreat through September and October. The contrast between the calm-looking quarterly result and the stock's wide daily range underscores the outsized influence of single-session news events on this micro-cap name.

What Drove BIVI Stock Price in the Last 30 Days

The 30-day advance was fueled largely by a concentrated stretch of bezisterim-related news. In late October, BioVie presented results from the Phase 2 SUNRISE-PD trial in early Parkinson's disease at the American Neurological Association annual meeting, reporting statistically significant improvements in both motor and non-motor symptoms among patients with elevated baseline inflammation, compared with placebo. The company also presented Phase 2 ADDRESS-LC data evaluating bezisterim in Long COVID.

Momentum continued with an invitation to present bezisterim Long COVID data at the National Institutes of Health's RECOVER-TLC workshop in late October, followed by the announcement that BioVie had been selected for a late-breaking oral presentation of bezisterim Long COVID data at the 4th Long COVID International Conference. These data-driven catalysts helped reverse the stock's mid-October decline.

Offsetting factors remained present throughout the period. A September financing agreement and related prospectus, together with the company's earlier going-concern disclosure, continued to weigh on sentiment and contributed to the slide toward the mid-October low before the clinical headlines drove the rebound.

What Drove BIVI Stock Performance Over the Last Quarter

The trailing quarter was defined by exceptional volatility rather than a single directional trend. In early August, the stock experienced a rapid selloff to an intraday low of $0.82, followed days later by a dramatic spike to an intraday high of $3.79 on extraordinarily heavy volume. BioVie filed its annual report for the fiscal year ended June 30 in mid-August, which included a going-concern disclosure reflecting substantial doubt about the company's ability to continue as a going concern absent additional capital.

Through September and October, the stock generally drifted lower as investors weighed financing needs, dilution risk, and the company's cash position against a clinical pipeline that still lacks approved products. The late-quarter recovery into early November was driven primarily by the renewed cadence of bezisterim data presentations rather than by any change in the company's underlying financial profile.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a broader platform of hundreds of bots trading thousands of tickers. Only top-performing and most relevant bots appear in this section, which is designed to help users quickly identify strategies gaining traction. These bots vary widely in strategy, trading timeframe, and performance metrics, ranging from short-term intraday approaches to longer-horizon models, so they may suit different risk tolerances and objectives. The page provides a practical starting point for traders interested in data-driven, rules-based approaches to the market. Explore Trending AI Robots to review the currently featured strategies.

BIVI Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, the most important variables for BIVI are clinical and financial. Investors will likely focus on the next quarterly earnings report, expected in November 2026, for updates on cash runway, operating expenses, and any financing plans. Continued bezisterim data disclosures, including longer-term Parkinson's and Long COVID results, and progress toward the Phase 3 Alzheimer's program, remain central to the investment thesis.

Regulatory and development milestones for BIV201 in liver cirrhosis and ascites also carry weight. Financial risks, including the going-concern disclosure, potential future equity raises, and shareholder dilution, are material and could pressure the stock regardless of positive clinical news. Broader biotechnology sentiment and interest-rate expectations may likewise influence a small-cap, pre-revenue name such as BIVI. A limited analyst following currently assigns an average rating of Strong Buy with a 12-month price target near $5.26, though such targets carry substantial uncertainty for a clinical-stage company.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations